Kinaset Therapeutics intends to develop novel therapeutics that can positively impact people affected by intractable diseases, including severe asthma. The firm's novel lead asset and experienced team combine a potentially best in class approach to treating severe asthma with a group of dedicated drug development experts working to bring the therapy forward.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 11/30/20 | $40,000,000 | Series A |
5AM Ventures Atlas Venture GIMV | undisclosed |
